Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

224 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state.
Lissoni P, Paolorossi F, Ardizzoia A, Barni S, Chilelli M, Mancuso M, Tancini G, Conti A, Maestroni GJ. Lissoni P, et al. Among authors: tancini g. J Pineal Res. 1997 Aug;23(1):15-9. doi: 10.1111/j.1600-079x.1997.tb00329.x. J Pineal Res. 1997. PMID: 9379341 Clinical Trial.
Chemotherapy and angiogenesis in advanced cancer: vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer.
Lissoni P, Fugamalli E, Malugani F, Ardizzoia A, Secondino S, Tancini G, Gardani GS. Lissoni P, et al. Among authors: tancini g. Int J Biol Markers. 2000 Oct-Dec;15(4):308-11. doi: 10.1177/172460080001500405. Int J Biol Markers. 2000. PMID: 11192826 Free article. Clinical Trial.
A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
Lissoni P, Vaghi M, Ardizzoia A, Malugani F, Fumagalli E, Bordin V, Fumagalli L, Bordoni A, Mengo S, Gardani GS, Tancini G. Lissoni P, et al. Among authors: tancini g. In Vivo. 2002 Mar-Apr;16(2):93-6. In Vivo. 2002. PMID: 12073777 Clinical Trial.
224 results